primary progressive multiple sclerosis
Neurology · 2017–2020
2decisions
1medicine
2carried consumer input
72individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ocrelizumab Treatment of early, active primary progressive multiple sclerosis (PPMS) to delay the progression of physical disability in patients diagnosed within the… | Jul 2020 | Not recommended | 9 individuals MS Australia · MS Research Australia |
| ocrelizumab Treatment of primary progressive multiple sclerosis (PPMS) to delay the progression of physical disability. | Nov 2017 | Not recommended | 63 individuals |
Who spoke
MS Australia · MS Research Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.